Peptide Library / Detail
Pramlintide
Half-life
~45–60 minutes (SC); pharmacodynamic effects ~2–3 hours
Delivery
Subcutaneous injection immediately prior to major meals (separate site from insulin).
Dosage
—
Research Use Only
All products listed are for laboratory research only — not for human consumption. By browsing, you acknowledge these terms.
Purchase
Description
Pramlintide is a synthetic analog of human amylin, a beta-cell co-secreted peptide with insulin. In research settings it’s used to study postprandial glucose control, gastric emptying, satiety, and glucagon suppression.
Usage
Investigated as an adjunct to mealtime insulin to model reductions in postprandial hyperglycemia and appetite, and to explore amylin physiology in metabolic studies.
Mechanism of Action
Activates amylin receptors to slow gastric emptying, suppress inappropriate postprandial glucagon secretion, and enhance satiety—thereby reducing postprandial glucose excursions.
Benefits(4)
- Reduces postprandial glucose excursions
- Decreases glucagon surge after meals
- Slows gastric emptying
- May reduce appetite and caloric intake
Side Effects(5)
- Nausea, vomiting, abdominal discomfort
- Decreased appetite
- Injection-site reactions
- Hypoglycemia when used with insulin (requires mealtime insulin dose reduction)
- Boxed warning: severe insulin-induced hypoglycemia risk, especially within 3 hours post-dose